Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Arena Pharmaceuticals's stock reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Monday, August, 7th. The company reported ($0.77) EPS for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.03. The company had revenue of $6.49 million for the quarter, compared to analysts' expectations of $5.58 million. Arena Pharmaceuticals had a negative net margin of 16.27% and a negative return on equity of 49.87%. The business's quarterly revenue was down 31.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.10) EPS. View Arena Pharmaceuticals' Earnings History.

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Arena Pharmaceuticals.

7 equities research analysts have issued 12 month target prices for Arena Pharmaceuticals' stock. Their forecasts range from $19.00 to $60.00. On average, they expect Arena Pharmaceuticals' stock price to reach $38.83 in the next year. View Analyst Ratings for Arena Pharmaceuticals.

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

• 1. Needham & Company LLC analysts commented, "Arena mgmt hosted a conference call yesterday to provide a 2Q17 quarterly corporate update. Company announced positive results from a 61-pt Phase 2 trial of ralinepag in Pulmonary Arterial Hypertension (PAH) in Jul 2017. We await insight into FDA and EMA requirements for registration. Mgmt is not providing specific guidance, but we assume mtgs can be scheduled by YE17. Other upcoming milestones include top-line results from Phase 2 trials of etrasimod in Ulcerative Colitis (YE17) and APD-371 in pain associated with Crohn’s Disease (YE17)." (8/8/2017)
• 2. Cantor Fitzgerald analysts commented, "We continue to view Phase 2 data as about as good as it gets. Despite facing comparisons with Phase 2 data for a drug, selexipag, that benefited from trial idiosyncrasies (subject randomization imbalances), the improvement in pulmonary vascular resistance (PVR) associated with treatment in the ralinepag Phase 2 trial (-30% vs. placebo and -20% vs. baseline) was at the high end of a range of effects noted to us by a physician knowledgeable in the care of patients with PAH and the development of therapies for it." (7/17/2017)
• 3. According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October 2016. Though sales of Belviq have been lackluster so far, the company partnership agreements and efforts to improve Belviq’s performance is impressive. We are encouraged by the company’s cost reduction initiatives to streamline the organization to support its development programs. Moreover, the company’s decision to shift its priorities to its proprietary clinical-stage pipeline is also encouraging. The company recently announced positive results on its PAH candidate, ralinepeg. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates that are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players." (7/4/2017)

Some companies that are related to Arena Pharmaceuticals include Immunomedics (IMMU), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Esperion Therapeutics (ESPR), Genus plc (GNS), Medpace Holdings (MEDP), Genomic Health (GHDX), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Spectrum Pharmaceuticals (SPPI), Momenta Pharmaceuticals (MNTA), Cellectis S.A. (CLLS), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Enanta Pharmaceuticals (ENTA), Albany Molecular Research (AMRI), BeyondSpring (BYSI), Heron Therapeutics (HRTX) and CRISPR THERAPTC (CRSP).

Arena Pharmaceuticals' management team includes the folowing people:

• Amit D. Munshi, President, Chief Executive Officer, Director
• Kevin R. Lind, Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
• Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary
• Vincent E. Aurentz, Executive Vice President and Chief Business Officer
• Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer
• Maurice J. Mezzino, Senior Vice President - Corporate Development
• Tina Susan Nova Ph.D., Lead Independent Director
• Donald D. Belcher, Director
• Jayson Dallas M.D., Director
• Oliver S. Fetzer Ph.D., Director

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $25.56.